7 December 2020 - A decision by PHARMAC to defer the approval of two new drugs for the treatment of diabetes until next year is worse than disappointing according to National Hauora Coalition clinical director Dr Rawiri McKree Jansen.

Jansen has been an outspoken critic of PHARMAC's original proposal to provide empagliflozin and dulaglutide for only 50,000 people with the condition.

It would have required patients to show they were at risk of complications such as heart and kidney disease before receiving the drugs.

Read Radio New Zealand article